Straumann Group Brand Tiers Brand Tiers _(title alanına `Straumann Group `, titleAccent alanına `Brand Tiers`.)_

/ One parent, several brands, openly different tiers

The corporate structure behind some of the most quoted implant names in dental tourism is public, and it is worth reading in the company's own words. Straumann Group's brand page lists Straumann, Neodent, Medentika, Anthogyr and ClearCorrect as its global brands, and describes them differently: Straumann as "the world-leading brand for confidence in esthetic dentistry", Neodent as "straightforward and progressive dental solutions enabling affordable access to implant therapy", Medentika as "prosthetics perfected, implants engineered and made in Germany", Anthogyr as "ingenuity-driven performance in dental implantology".

The segmentation behind those descriptions is also the group's own. A feature story in its 2019 annual report, titled "Our strategy to become a leader in all price segments", explains that the company could not continue "as an exclusively premium company", took its first step into the "upper value segment" by investing in Brazil's Neodent in 2012, then "intensified our efforts to penetrate the upper value segment by joining forces with Medentika in Germany and Anthogyr in France", and then moved into the "lower value segment" with T-Plus (Taiwan), equinox (India), Zinedent (Türkiye), distribution rights for Korea's Warantec, and a new Brazilian-made brand, nuvo.

None of this is a leak or an accusation. It is a strategy the company describes with justified confidence, and the value brands exist precisely to make implant treatment affordable for people who could not otherwise have it, which is a good thing. The problem this article addresses sits one step downstream: what happens when the group name is used on a patient quote in place of the brand name.

/ What the premium tier actually buys

The measurable difference between tiers is not that one implant works and another does not. It is evidence depth, material and surface technology, and the component ecosystem. The Straumann brand's flagship asset is time: its SLA surface (sandblasted, large-grit, acid-etched, the generic description behind the brand name) has follow-up data few products anywhere can match. A retrospective study of 511 SLA implants in 303 partially edentulous patients reported 98.8% survival and 97.0% success at 10 years, with a 1.8% prevalence of peri-implantitis over the decade (PubMed 22897683). Long horizons like this are the substance behind the word premium.

The full picture includes the limits of premium features too. SLActive, the hydrophilic successor surface marketed for faster early healing, was compared with standard SLA in a systematic review of six randomized controlled trials covering 326 implants: implant stability measured by ISQ was comparable between the two surfaces over 12 weeks in the maxilla and mandible, with the measured SLActive advantage confined to specific placement scenarios (PubMed 39775154). Roxolid, the brand name for Straumann's titanium-zirconium alloy used in narrow implants, has supportive published data: a systematic review of Ti-Zr narrow-diameter implants pooled 922 implants with survival of 98.4% at one year and 97.7% at two years (PubMed 26852292), and a later meta-analysis of single-crown cases found 97.5% cumulative survival up to 36 months, with no measured difference against pure-titanium implants (PubMed 37331853).

Read together, these numbers say something more useful than a slogan: the premium tier's strongest verified asset is the length and volume of its evidence, while individual premium features can show equivalence rather than superiority in trials. Both halves belong in a complete account. What surface brand names mean generically, and how surfaces measurably differ across manufacturers, is covered in our terminology decoder; a five-year meta-analysis comparing three manufacturers' surfaces on marginal bone found real, statistically significant differences between them (PubMed 33270049), which is exactly why the brand line on your plan is worth a written answer.

/ Neodent: the value tier with actual data

Neodent is the group's Brazilian brand, described by the group itself as enabling "affordable access to implant therapy", and it is the value-tier name UK and US patients most often meet on quotes. It is not an obscure product: its Grand Morse line is documented on the group's own professional pages, and its clinical record is being published. The largest recent dataset is a retrospective cohort of 4,783 Neodent hybrid-macrogeometry implants (Helix and GM lines) in 1,215 patients, reporting a survival rate of 95.4% at a mean follow-up of 29.5 months, including many medically compromised patients and a high share of immediate loading (PubMed 41463602).

Two qualifications belong next to that figure, and both are visible in the paper itself. First, the follow-up is short next to the 10-year Straumann data above; a mean of two and a half years answers a different question than a decade does. Second, the study is affiliated: its senior authors include Neodent's scientific president and a board member, disclosed in the conflict-of-interest statement. Disclosure is proper practice, not a scandal, but a patient weighing tiers should know that the value tier's largest dataset is younger and closer to the manufacturer than the premium tier's.

What this means practically: being quoted Neodent is not a trick, and for many cases it is a rational, openly value-positioned choice from a serious manufacturer. The failure mode is different, and it is the one this article exists for: being allowed to believe you bought the premium brand when the plan meant the value brand. The two are corporate siblings, not synonyms. If your quote says Neodent, it should say Neodent, and you can then weigh its real record; we look at that record in more depth in our Neodent article.

/ Medentika: the component brand on patient quotes

Medentika is the group's German brand, positioned on the group's own page with the phrase "prosthetics perfected". Its centre of gravity is prosthetic components: abutments and connection parts, including parts engineered for compatibility with other manufacturers' implant systems. Its web presence points the same direction; medentika.com currently redirects to a dental-professionals page on straumann.com, not to a patient product site. This is a business-to-business brand that has come to appear, by name, on patient-facing quotes in dental tourism.

Here is the plain data statement patients are rarely given. Searching PubMed for the brand, we found component, accuracy and compatibility studies, but no brand-specific clinical survival study of Medentika implants that we could cite for a survival figure. So this article does not quote one; there is no verified number to quote. That is not a coded warning. Absence of brand-named survival literature is common for component-centred brands, and CE marking, ISO manufacturing and the parent group's engineering stand behind the products. But the difference between "no published brand-specific survival data" and "95.4% at 29.5 months" and "98.8% at 10 years" is exactly the difference the single phrase "Straumann Group" flattens.

There is also a sound argument for Medentika on a quote, and it is the one least often made: a components company inside a global group is a reasonable answer to the travelling patient's biggest structural worry, which is whether anyone at home can service the restoration later. If a clinic proposes Medentika, the productive questions are which implant line, what the written warranty covers, and how parts are sourced in your home country; we expand on those in our Medentika decoder article.

/ Reading "Straumann Group" on a quote

Now the practical core. When a treatment plan or price list says "Straumann Group implant", every brand in this article satisfies that sentence: the Swiss premium product, the Brazilian value product, the German component brand, the French brand, and the group's lower-value lines. The phrase is corporately true and commercially empty. In a market where these names are routinely listed side by side, tier-blind wording is where substitution lives, sometimes intentionally and sometimes through nothing worse than a copied template.

The protection is boring paperwork, and it works. Before you pay anything, the plan should name the brand and the implant line, in writing: not "Swiss quality group implant" but the exact product family. After surgery, you should receive the implant card that EU medical-device rules require for implanted devices, identifying the device; keep it, photograph it, and check the brand on it against your plan. If the abutment or crown parts are third-party compatible rather than original, that too can simply be asked and written down. A clinic loses nothing by answering; we publish who does the work here and answer exactly these questions through our contact page before anyone books a flight.

One more calibration, so this article is not misread as premium evangelism. The right implant for a case is a clinical decision in which bone, prosthetic plan, budget and serviceability all matter; there are cases where a value-tier implant is the sensible recommendation and saying otherwise would be salesmanship in the other direction. The tier is not the scandal. The unnamed tier is. Whether the implant is placed here or anywhere else, insist on the name, and treat any reluctance to write it down as information. Broader implant planning questions, from bone grafting to loading protocols, are covered on our implant treatment page and in the all-inclusive pricing guide, where the same write-it-down discipline is applied to money.